Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 13/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 10/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16402065 | 0.85 | FEN1 (0.42) | FEN1ALOX5APCLK1 | |
| SCHEMBL21819775 | 0.80 | ALDH1A1 (0.48) | FEN1ALOX5APCLK1 | |
| SCHEMBL29646646 | 0.80 | ALDH1A1 (0.48) | FEN1ALOX5APCLK1 | |
| SCHEMBL4513696 | 0.74 | FEN1 (0.65) | FEN1ALOX5APTDO2 | |
| SCHEMBL11545227 | 0.73 | TAAR1 (0.50) | FEN1ALOX5APPDE3BPDE3A | |
| SCHEMBL16342565 | 0.72 | PTGS2 (0.45) | FEN1ALOX5APCLK1 | |
| SCHEMBL30296616 | 0.72 | CYP2A6 (0.44) | FEN1ALOX5APPDE3BPDE3ACYP2E1 | |
| SCHEMBL26459083 | 0.72 | CYP2A6 (0.44) | FEN1ALOX5APPDE3BPDE3ACYP2E1 | |
| SCHEMBL16395977 | 0.72 | ALDH1A1 (0.41) | FEN1ALOX5APCLK1 | |
| SCHEMBL19433368 | 0.72 | APP (0.43) | FEN1ALOX5APCLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562912-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2020-02-18 | — | — | US | disclosed |
| EP-3004057-B1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS | C&C RES LAB (KR) | 2018-07-25 | — | — | EP | disclosed |
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2016-04-21 | — | — | US | disclosed |
| EP-3004057-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014196793-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | STAT3, JAK2, STAT5A | FEN1 4643/4885ALOX5AP 3965/4885FGFR1 746/4885 |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, STAT5A | FEN1 4643/4885ALOX5AP 3965/4885FGFR1 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.